Reuters: Regulatory News: EU body wants new guidance on Boehringer clot drug

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

EU body wants new guidance on Boehringer clot drug May 25th 2012, 09:25 LONDON | Fri May 25, 2012 5:25am EDT LONDON May 25 (Reuters) - Doctors and patients should be given clearer guidance on how to avoid bleeding risks when using Boehringer Ingelheim's new stroke prevention pill Pradaxa, European regulators said on Friday. The European Medicines Agency said data continued to confirm the positive benefit-risk balance of the anticoagulant medicine, despite cases of fatal bleeding, but advice on the risks should be strengthened. Pradaxa is the first in a new class of medicines aimed at replacing the old and problematic drug warfarin. It is designed for use after hip and knee surgery and to prevent strokes in patients with atrial fibrillation, a form of irregular heartbeat common among the elderly. Rival drugs include Xarelto, from Bayer and Johnson & Johnson, and Eliquis, from Bristol-Myers Squibb and Pfizer.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions